HUNTSVILLE, Ala., Nov. 12, 2020 /PRNewswire/ — Discovery Life Sciences™ (Discovery), a world chief in biospecimen options, genomic, cell, and immunohistochemistry (IHC) companies, pronounces the addition of Illumina’s TruSight Oncology 500 (TSO500) expertise to HudsonAlpha Discovery, Discovery’s extremely acknowledged and regarded sequencing and bioinformatics laboratory.
Illumina’s TSO500 strong Tumor (FFPE) and cfDNA expertise permits genomic characterization throughout a broad vary of tumor varieties by way of the identification of germline and somatic variants from DNA and RNA, together with vital immuno-oncology SNV, InDel, CNV, and fusion biomarkers, in addition to microsatellite instability (MSI) and tumor mutational burden (TMB). HudsonAlpha Discovery’s TSO500 platform mixed with Discovery Life Sciences’ complete biospecimen options will speed up immuno-oncology and liquid biopsy biomarker research by way of supply of actionable NGS information throughout patient-matched tumor and plasma biospecimens. The outcome will probably be a major enhancement of the data derived from most cancers diagnostic research and immunotherapeutic scientific analysis applications.
“HudsonAlpha Discovery’s TSO500 companies are optimized for effectivity to allow speedy supply of the dear NGS information that solely TSO500 gives throughout matched FFPE and plasma samples at any scale,” mentioned Dr. Shawn Levy, PhD, Chief Scientific Officer at Discovery Life Sciences. “We’re assured these new companies will advance biomarker applications and permit researchers to extra shortly develop and validate new immunotherapeutics, liquid biopsy diagnostics and companion diagnostics.”
“HudsonAlpha Discovery’s addition of our TSO500 platform is a major step ahead within the wider adoption of our revolutionary pan-cancer expertise,” mentioned Mark Van Oene, Illumina’s Chief Industrial Officer. “We’re excited to see our expertise in Discovery’s knowledgeable palms. The mixture of our expertise with Dr. Levy and his workforce will present HudsonAlpha Discovery’s shoppers a singular and worthwhile useful resource to speed up the event of latest precision drugs therapies and diagnostic instruments.”
Discovery’s sequencing and bioinformatics laboratory, HudsonAlpha Discovery, gives a collection of long-read, short-read and single cell sequencing applied sciences – together with Illumina, 10x Genomics, Pacific Biosciences and Oxford Nanopore platforms, and variant discovery bioinformatic pipelines.
About Discovery Life Sciences
Discovery Life Sciences is the worldwide market chief in biospecimen evaluation, procurement, distribution, and scientific companies for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s globally acknowledged sequencing and bioinformatics division that leverages probably the most present genomic analysis applied sciences to comprehensively assist discovery, translational, and scientific analysis. Pushed by science, the Discovery workforce engages with prospects in an revolutionary, consultative method to overcoming obstacles and reaching a sooner finish outcome. We’re Science at your Service™! For extra info, go to dls.com.
SOURCE Discovery Life Sciences